
Sharon M. Moe, MD
Distinguished Professor
Bio
Titles & Appointments
- Stuart A. Kleit Professor of Nephrology
- Professor of Medicine
- Adjunct Professor of Anatomy & Cell Biology
- Division Director
- Adjunct Professor for Anatomy and Cell Biology
- Nephrology Section Chief, Eskenazi Health
My research investigates the relationship of kidney disease, vascular calcification, bone, and disorders of mineral metabolism known as CKD-Mineral Bone Disorder (CKD-MBD). Our research is funded by the NIH, Veterans Administration, Food and Drug Administration, and industry and utilizes in vivo, ex vivo and in vitro techniques to investigate the pathophysiology of arterial medial calcification and bone disease. We are using a naturally occurring rat model of CKD that spontaneously develops all manifestations of CKD-MBD to study 1) mechanisms by which matrix vesicles propagate arterial calcification, 2) how oxidative stress alters vasculature, 3) the role of advanced glycation end product cross linking of bone collagen predisposes to fracture, 4) mechanisms of sudden cardiac death, 5) how impaired muscle function occurs with progressive CKD, and 6) micro RNA as biomarkers. We also have active investigator initiated clinical trials studying the natural progression of frailty and muscle weakness in patients as they start on dialysis, novel phosphate binders and the effect on phosphate balance, how nutrition can be enhanced in patients on dialysis, and the use of pioglitazone as a treatment for ADPKD.
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
Renal Osteodystrophy or Kidney-Induced Osteoporosis?
Moving Beyond the Assumed: Improving Fistula Success Rates.
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Calcium Homeostasis in Health and in Kidney Disease.
Fractures in Patients with CKD: Time for Action.
Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model.
Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease.
Calcium as a cardiovascular toxin in CKD-MBD.
Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.
Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
ASN Presidential Address 2014: Moving Past Nephrology's Midlife Crisis.
The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.
Bone marrow fat is increased in chronic kidney disease by magnetic resonance spectroscopy.
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease.
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Pathogenesis of arrhythmias in a model of CKD.
Adipocyte induced arterial calcification is prevented with sodium thiosulfate.
Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease.
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.
Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD).
Recent advances in the noninvasive diagnosis of renal osteodystrophy.
Transglutaminase 2 accelerates vascular calcification in chronic kidney disease.
Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
Vascular calcification: pathophysiology and risk factors.
Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.
Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.
CKD-mineral and bone disorder: core curriculum 2011.
The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Calcimimetics inhibit renal pathology in rodent nephronophthisis.
Efficacy of sodium thiosulfate for the treatment for calciphylaxis.
Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease.
Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question.
Confusion on the complexity of calcium balance.
Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.
RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC).
A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.
Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.
Calcimimetic inhibits late-stage cyst growth in ADPKD.
R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
Medication changes based on echocardiography in dialysis patients.
Review article: Chronic kidney disease-mineral bone disorder: have we got the assays right?
Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells.
A rat model of chronic kidney disease-mineral bone disorder.
Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells.
Improving global outcomes in mineral and bone disorders.
Precision of biomarkers to define chronic inflammation in CKD.
Disorders involving calcium, phosphorus, and magnesium.
Association of hepatitis C virus infection with prevalence and development of kidney disease.
Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.
Chronic kidney disease-mineral-bone disorder: a new paradigm.
Mechanisms of vascular calcification in chronic kidney disease.
Vitamin D, cardiovascular disease, and survival in dialysis patients.
High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells.
Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins.
Uremic vascular calcification.
Vascular calcification: Hardening of the evidence.
Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis.
The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells.
Vascular calcification and renal osteodystrophy relationship in chronic kidney disease.
The case against calcium-based phosphate binders.
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States.
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD).
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
The role of vitamin D in vascular calcification in chronic kidney disease.
[Vascular calcification in end stage renal disease].
American Medical Association
American Society for Clinical Investigation
American Board of Internal Medicine - Nephrology